Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Motif Bio losses narrow on lower R&D spend

Tuesday, 25th September 2018
Antibiotics developer Motif Bio booked a narrowing of first half losses after it cut back on R&D spending.

Net losses for the six months through June narrowed to $7.8m, from $29.7m on-year.

'We made tremendous progress during the first half of 2018, including completing the submission of an new drug application with the FDA for iclaprim in acute bacterial skin and skin structure infections,' chief executive Graham Lumsden said.

The application was accepted for review in August with confirmation of a priority review from FDA resulting in an approval date of February 13, 2019.

'We are continuing to build on our achievements and are working to increase awareness and understanding of Motif Bio and iclaprim with potential commercialization partners, the medical community and investors,' Lumsden said.

Story provided by

Related Shares: Motif Bio

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.